Our results support the idea that LATS2 expression could be reduced by an alternative mechanism, rather than promoter hypermethylation, which is the upregulation of miR-363, leading to the acquisition of TX resistance in ovarian cancer cells. The gene discussed is LATS2; the disease is ovarian cancer.